inhibitor
class
newli
develop
antidiabet
drug
preserv
incretin
hormon
promot
postprandi
insulin
secret
although
cardiovascular
effect
inhibit
substanti
studi
exact
role
cardiovascular
diseas
especi
human
remain
elus
previou
small
studi
metaanalys
suggest
benefit
surrog
outcom
cardiovascular
event
agent
howev
grow
evid
recent
year
question
cardioprotect
effect
signal
heart
failur
hospit
recent
larg
scale
clinic
trial
savortimi
call
question
safeti
agent
util
treatment
cardiovascular
diseas
review
revisit
physiolog
function
discuss
role
cardiometabol
diseas
base
recent
experiment
clinic
studi
also
known
membran
glycoprotein
well
known
role
catalyt
degrad
incretin
inhibitor
class
antidiabet
medic
accept
worldwid
owe
eas
administr
modest
effect
lack
seriou
side
effect
inhibit
experiment
model
uniformli
demonstr
cardioprotect
effect
inde
earli
metaanalys
phase
iiiii
data
use
context
glycemia
lower
shown
favor
protect
effect
class
term
cardiovascular
cv
endpoint
lead
widespread
expect
drug
show
benefit
appropri
design
efficaci
trial
cv
standpoint
howev
recent
complet
appropri
design
phase
iii
trial
intent
demonstr
benefit
cv
perspect
shown
signific
improv
primari
cv
endpoint
patient
treat
compar
placebo
review
summar
structur
function
known
role
physiolog
also
review
import
pathophysiolog
cardiometabol
disord
provid
recent
clinic
trial
evid
test
effect
cv
diseas
transmembran
glycoprotein
form
homodim
tetram
plasma
membran
cleav
ntermin
dipeptid
protein
prolin
alanin
penultim
amino
acid
highli
conserv
among
speci
term
amino
acid
sequenc
shown
figur
ntermin
cytoplasm
domain
transmembran
domain
larg
ctermin
extracellular
domain
extracellular
compon
contain
hydrolas
domain
eightblad
propel
domain
domain
respons
dipeptidylpeptidas
activ
bind
protein
adenosin
deaminas
ada
fibronectin
residu
residu
within
cysteinerich
segment
shown
essenti
ada
bind
residu
critic
catalyt
activ
figur
wide
express
mani
organ
kidney
spleen
lung
pancrea
prostat
express
high
level
endotheli
cell
differenti
epitheli
cell
immun
cell
cell
dendrit
cell
macrophag
also
present
plasma
solubl
form
either
come
shed
process
driven
proteinas
releas
circul
mean
vesicl
exosom
ectosom
apoptot
bodi
alter
express
solubl
commonli
seen
mani
disord
solid
tumor
autoimmun
diseas
hepat
c
type
diabet
obes
regul
express
fulli
understood
studi
suggest
hepatocyt
nuclear
mediat
transcript
vitro
experi
cotransfect
enhanc
report
gene
express
control
promot
promot
region
also
contain
ga
interferon
gammaactiv
sequenc
motif
bind
site
inde
activ
administr
interferon
retino
acid
lead
bind
ga
motif
subsequ
transcript
addit
transcript
regul
also
regul
posttranscript
level
enhanc
translat
transcript
activ
lymphocyt
mani
cytokin
also
involv
regul
express
shown
respons
upregul
fibroblast
epitheli
cell
stromal
cell
polar
h
tgf
also
show
increas
express
incretin
peptid
gastric
inhibitori
polypeptid
gip
glucagonlik
peptid
respons
modul
postprandi
blood
glucos
promot
insulin
secret
pancreat
cell
via
glucagonostat
effect
gip
rapidli
inactiv
lead
short
halflif
minut
gip
mice
lack
protect
develop
dietinduc
obes
demonstr
improv
postprandi
glucos
control
pairfeed
indirect
calorimetri
studi
shown
reduc
food
intak
increas
energi
expenditur
account
resist
dietinduc
obes
mice
mice
also
demonstr
improv
insulin
sensit
reduc
pancreat
islet
hypertrophi
protect
streptozotocininduc
cell
loss
hyperglycemia
pharmacolog
inhibit
enzymat
activ
improv
glucos
toler
wildtyp
mice
inhibit
also
improv
glycem
control
mice
suggest
addit
mechan
inhibitionmedi
antihyperglycem
effect
addit
incretin
peptid
also
cleav
number
protein
physiolog
target
includ
brain
natriuret
peptid
bnp
peptid
yy
stromalcellderiv
erythropoietin
granulocyt
colonystimul
factor
gcsf
substanc
p
pharmacolog
target
evid
provid
vitro
cell
cultur
andor
incub
experi
substrat
includ
gastrinreleas
peptid
growthhormonereleas
factor
macrophag
deriv
chemokin
eotaxin
ifn
induc
granulocytemacrophag
colonystimul
factor
erythropoietin
neuropeptid
btype
natriuret
peptid
peptid
yy
catalyt
activ
extens
review
elsewher
discuss
detail
addit
peptidas
activ
also
possess
noncatalyt
function
via
interact
rang
ligand
includ
ada
fibronectin
coronaviru
spike
protein
collagen
insulinlik
growth
factor
receptor
fibroblast
activ
protein
interact
ligand
play
role
varieti
process
enhanc
cell
activ
function
modul
antigen
present
cell
apc
costimulatori
function
first
describ
earli
ligat
ada
antibodi
recogn
ada
bind
epitop
enhanc
cell
activ
prolifer
cytokin
product
crosslink
antibodi
induc
tyrosin
phosphoryl
subset
protein
phosphoryl
molecul
includ
signal
molecul
downstream
fyn
map
kinas
ccbl
phospholipas
c
sinc
short
intracellular
domain
aa
reli
protein
transduc
signal
cell
torimoto
et
al
report
activ
ligand
lead
coaggreg
lipid
raft
suggest
may
transduc
costimul
via
result
consist
observ
high
cell
restrict
cell
cell
lack
trigger
elicit
memori
cell
respons
discuss
interact
may
also
promot
cell
activ
degrad
adenosin
immunosuppress
metabolit
addit
interact
may
form
complex
consist
b
kinas
lipid
raft
cell
membran
lead
activ
nfb
respiratori
syndrom
mer
viral
respiratori
ill
first
report
saudi
arabia
caus
infect
coronaviru
merscov
mortal
mer
approxim
subsequ
identifi
function
receptor
entri
merscov
human
bat
cell
engag
merscov
spike
protein
mediat
viral
attach
intern
residu
involv
viru
bind
ident
ada
bind
domain
indic
potenti
competit
bind
human
macaqu
hors
rabbit
suggest
abl
bind
merscov
therefor
suscept
infect
howev
small
anim
mice
diverg
respect
viru
bind
region
suscept
merscov
infect
previous
report
cofactor
entri
hiv
cell
howev
subsequ
studi
identifi
major
coreceptor
hiv
coexpress
may
partial
explain
associ
express
hiv
infect
ohnuma
et
al
report
interact
present
apc
initi
signal
cascad
antigen
load
apc
result
activ
upon
bind
phosphoryl
result
phosphoryl
disassoci
tollip
phosphoryl
activ
nfkappa
b
nf
b
turn
upregul
interact
report
involv
pathogenesi
arthriti
also
report
bind
multipl
compon
extracellular
matrix
collagen
fibronectin
tat
protein
interact
matrix
compon
may
play
role
sequestr
allow
addit
function
matrix
remodel
metastasi
chemotaxi
circul
activ
report
increas
patient
obes
posit
correl
level
degre
obes
measur
insulin
resist
inflamm
lugari
et
al
report
increas
circul
activ
diabet
patient
result
reduct
plasma
fast
respons
meal
addit
circul
activ
express
cell
dendrit
cell
also
increas
patient
howev
also
report
suggest
decreas
circul
activ
patient
potenti
contradict
may
relat
fact
studi
mani
patient
concomit
medic
sever
wide
use
antidiabet
medic
includ
thiazolidinedion
pioglitazon
metformin
report
reduc
circul
express
cell
may
reflect
improv
glycem
control
measur
inflamm
result
reciproc
decreas
express
enhanc
express
hepat
also
report
nonalcohol
fatti
liver
diseas
express
may
advers
affect
glucos
metabol
condit
vitro
stimul
cell
high
glucos
increas
express
wherea
insulin
fatti
acid
cholesterol
incretin
hormon
gip
potenti
insulin
secret
pancreat
cell
gproteincoupl
receptor
mention
gip
inactiv
result
short
halflif
less
min
less
min
rodent
min
human
gip
patient
incretin
respons
attenu
increas
plasma
enzymat
activ
well
heighten
tissu
express
releas
tissu
viscer
adipos
increas
level
express
correl
degre
glycemiainsulin
resist
suggest
mediat
incretin
degrad
involv
pathogenesi
sever
approv
approv
fda
eu
antidiabet
drug
sitagliptin
saxagliptin
linagliptin
vildagliptin
alogliptin
clinic
trial
demonstr
approxim
lower
patient
baselin
level
around
placebosubtract
reduct
gener
greater
patient
higher
baselin
gener
studi
also
corrobor
improv
homeostasi
model
assess
beta
cell
function
index
homa
fast
proinsulin
insulin
ratio
suggest
improv
cell
function
incid
side
effect
hypoglycemia
low
agent
clinic
trial
common
report
side
effect
includ
nasopharyng
upper
respiratori
tract
infect
urinari
tract
infect
headach
saxagliptin
linagliptin
recent
approv
fda
contrast
member
class
linagliptin
primarili
nonren
rout
excret
therefor
would
need
dose
adjust
regardless
renal
impair
addit
approv
drug
includ
dutogliptin
gemigliptin
develop
await
fda
approv
inflamm
play
key
pathogen
role
develop
insulin
resist
innat
immun
mechan
typifi
macrophag
infiltr
activ
wide
believ
repres
major
mediat
adipos
inflamm
howev
recent
find
suggest
cell
may
also
play
import
role
process
activ
effector
cell
shown
promot
adipos
inflamm
enhanc
macrophag
recruit
activ
cell
especi
h
regulatori
cell
cell
subpopul
express
lowest
level
suggest
protect
develop
adipos
inflamm
insulin
resist
mention
provid
cell
costimulatori
signal
therefor
might
play
role
develop
adipos
inflamm
insulin
resist
although
lack
direct
evid
addit
mediat
costimulatori
signal
interact
adenosin
deaminas
ada
may
also
facilit
cell
activ
provid
suitabl
microenviron
cell
prolifer
inherit
mutat
ada
activ
caus
sever
combin
immunodefici
scid
human
mice
extracellular
atp
adp
initi
convert
amp
produc
adenosin
adenosin
process
ada
convert
inosin
anchor
ada
onto
cell
surfac
modul
pericellular
adenosin
level
thu
regul
cell
activ
figur
absenc
ada
activ
result
accumul
adenosin
dosedepend
inhibit
cell
prolifer
jurkat
cell
express
mutant
devoid
ada
bind
activ
sensit
adenosinemedi
inhibit
cell
prolifer
contrast
cell
express
ada
surfac
much
resist
inhibitori
effect
adenosin
recent
demonstr
express
adipos
tissu
macrophag
involv
inflamm
insulin
resist
interact
ada
express
adipos
tissu
macrophag
higher
circul
increas
obes
insulin
resist
patient
furthermor
level
adipos
tissu
macrophag
posit
correl
degre
insulin
resist
antigen
present
cell
includ
macrophag
dendrit
cell
facilit
cell
prolifer
activ
noncatalyt
activ
catalyt
inhibit
addit
exogen
affect
capabl
stimul
cell
antigen
present
cellexpress
abl
bind
ada
promot
cell
activ
via
remov
suppress
effect
adenosin
result
suggest
antigen
present
cell
capabl
promot
inflamm
insulin
resist
noncatalyt
function
interestingli
murin
rat
bind
ada
although
adenoviru
deliveri
human
mous
develop
studi
merscov
infect
vivo
rodent
model
investig
interact
relev
human
diabet
current
unavail
biolog
signal
mediat
origin
identifi
pancreat
cell
wide
express
mani
tissu
organ
includ
lung
kidney
centralperipher
nervou
system
cardiovascular
system
receptor
express
cardiovascular
cell
includ
endotheli
cell
cardiomyocyt
coronari
smooth
muscl
cell
belong
famili
gproteincoupl
receptor
engag
lead
activ
adenyl
cyclas
stimulatori
gs
subunit
subsequ
accumul
camp
classic
respons
cell
pancreat
cell
exampl
cell
activ
activ
pka
subsequ
reduc
result
increas
increas
transcript
factor
insulin
via
campdepend
pathway
signal
may
also
induc
activ
increas
express
bclxl
two
antiapoptot
protein
evid
indic
signal
involv
cardioprotect
effect
inhibit
exampl
shown
acut
infus
improv
endotheli
dysfunct
patient
agonist
also
shown
stimul
prolifer
human
coronari
arteri
endotheli
cell
eno
pka
pathway
increas
endotheli
progenitor
cell
epc
suggest
role
pathway
develop
epc
moreov
increas
left
ventricular
develop
pressur
coronari
flow
isol
mous
heart
studi
confirm
protect
effect
endotheli
cell
mediat
increas
nitric
oxid
product
activ
appear
cardioprotect
effect
human
variou
anim
model
effect
contractil
blood
pressur
cardiac
output
appear
independ
antidiabet
effect
enzymat
inhibit
genet
delet
reduc
heart
infarct
size
ischem
model
preserv
vitro
treatment
cardiomyocyt
agonist
reduc
cleavag
apoptosi
induc
variou
stimul
tnf
hypoxia
lipidemia
zhao
et
al
report
increas
mapk
activ
nitric
oxid
product
express
isol
heart
thu
increas
myocardi
glucos
uptak
aerob
perfus
consist
nikolaidi
et
al
report
h
continu
infus
pmolkgmin
consciou
dog
increas
myocardi
glucos
uptak
left
ventricular
hemodynam
pretreat
mapk
inhibitor
could
inhibit
effect
howev
conflict
observ
effect
myocardi
contractil
report
abl
decreas
contractil
primari
cultur
adult
rat
cardiomyocyt
despit
increas
camp
level
addit
nm
perfus
reduc
left
ventricular
develop
pressur
nm
increas
left
ventricular
develop
pressur
langendorff
aerob
perfus
isol
mous
heart
studi
mice
suggest
absenc
increas
baselin
left
ventricular
develop
pressur
although
acut
administr
increas
heart
rate
blood
pressur
least
rodent
model
chronic
treatment
nmolkg
twice
daili
wk
display
mark
reduct
systol
blood
pressur
dbdb
mice
angiotensiniiinfus
mice
line
anim
studi
major
clinic
trial
also
report
reduct
blood
pressur
chronic
treatment
agonist
also
suggest
exert
protect
effect
atherosclerosi
continu
infus
week
reduc
neointim
format
foam
cell
format
atherosclerot
lesion
size
effect
may
relat
favor
effect
lipoprotein
metabol
infus
pmolkgmin
via
jugular
vein
reduc
triacylglycerol
absorpt
intestin
product
rat
hsieh
et
al
report
nmolkg
ip
sitagliptin
mgkg
gavag
reduc
postprandi
triacylglycerol
oral
fat
load
mice
wherea
mice
increas
plasma
level
triacylglycerol
oral
fat
load
human
studi
shown
acut
infus
pmolkgmin
suppress
postprandi
plasma
triacylglycerol
free
fatti
acid
level
shortterm
treatment
nmol
sc
inject
meal
day
decreas
plasma
vldltriacylglycerol
lipid
lower
effect
review
detail
previous
independ
manner
although
function
signific
effect
fulli
elucid
incub
isol
aorta
ring
enzymat
inhibitor
provid
direct
evid
show
inhibit
relax
aorta
pathway
alogliptin
inhibitor
induc
eno
akt
phosphoryl
ser
ser
resp
parallel
rapid
increas
nitric
oxid
inhibit
src
kinas
decreas
eno
akt
phosphoryl
respons
alogliptin
contrast
lack
effect
insulin
mediat
activ
enosakt
suggest
alogliptin
mediat
vasodil
src
kinas
mediat
effect
enosakt
also
shown
assist
angiogenesi
promot
epc
pathway
stromal
deriv
known
substrat
regul
epc
compar
four
week
sitagliptin
versu
addit
treatment
ad
baselin
metformin
andor
sulfonylurea
therapi
diabet
patient
fadini
cowork
demonstr
patient
inhibit
increas
epc
increas
may
also
affect
cardiovascular
function
regul
inflamm
highli
express
mani
inflammatori
cell
cell
regul
biolog
function
enzymat
nonenzymat
function
play
import
role
cell
activ
cell
activ
block
enzymat
inhibit
suppress
dipeptidylpeptidas
activ
result
reduc
product
cytokin
includ
ifnbi
peripher
blood
mononuclear
cell
cell
immunosuppress
cytokin
shown
upregul
inhibit
cell
transfect
mutant
devoid
enzymat
activ
display
reduc
activ
compar
cell
transfect
wildtyp
consist
find
addit
solubl
promot
recal
antigeninduc
prolifer
peripher
blood
lymphocyt
solubl
mutant
without
enzymat
activ
provid
direct
evid
enzymat
activ
involv
cell
activ
mention
previous
also
promot
inflamm
catalyt
independ
mechan
interact
ada
howev
also
report
indic
may
neg
regul
immun
respons
mice
defici
show
enhanc
sever
autoimmun
encephalomyel
reduc
tgf
increas
product
ifn
tnf
immun
myelin
oligodendrocyt
glycoprotein
inhibit
activ
also
shown
enhanc
hematopoiesi
preserv
colonystimul
factor
activ
immunosuppress
function
may
least
part
explain
lack
improv
cardiovascular
endpoint
patient
good
evid
inhibit
mediat
protect
effect
myocardi
infarct
hypertens
atherosclerosi
surviv
rate
infarct
size
significantli
improv
mice
lad
ligat
accompani
enhanc
prosurviv
signal
pathway
pakt
atrial
natriuret
peptid
cardiac
tissu
pharmacolog
inhibit
sitagliptin
also
enhanc
express
cardioprotect
protein
improv
function
recoveri
ir
injuri
murin
heart
sever
studi
anim
model
support
favor
effect
inhibit
improv
endotheli
function
blood
pressur
saxagliptin
treatment
instanc
shown
reduc
blood
pressur
spontan
hypertens
rat
effect
accompani
increas
aortic
glomerular
releas
compar
reduct
peroxynitrit
level
contrast
posit
effect
anim
experi
effect
endotheli
function
human
alway
posit
doubl
blind
studi
treatment
vildagliptin
week
improv
forearm
blood
flow
respons
intraarteri
deliv
acetylcholin
contrast
studi
use
flow
mediat
dilat
fmd
brachial
arteri
shown
diametr
opposit
result
one
studi
sitagliptin
alogliptin
actual
appear
worsen
fmd
use
treat
anoth
studi
sitagliptin
improv
fmd
associ
increas
cell
agon
inhibit
reduc
postprandi
triacylglycerol
rodent
human
studi
shown
infus
pmolkgmin
hour
suppress
postprandi
plasma
triacylglycerol
free
fatti
acid
level
shortterm
treatment
nmol
sc
inject
meal
day
decreas
plasma
vldltriacylglycerol
continu
infus
week
reduc
neointim
format
foam
cell
format
atherosclerot
lesion
size
mice
provid
week
alogliptin
treatment
shah
et
al
demonstr
inhibit
reduc
atherosclerot
plaqu
vascular
inflamm
atherosclerosi
prone
ldlr
apo
mice
howev
human
studi
reveal
contradictori
result
cardiovascular
effect
inhibitor
patil
et
al
report
recent
metaanalysi
includ
random
clinic
trial
patient
inhibit
therapi
patient
control
treatment
diabet
treatment
placebo
demonstr
inhibitor
safe
cardiovascular
standpoint
benefici
effect
cardiovascular
event
compar
diabet
medic
placebo
anoth
metaanalysi
trial
patient
perform
monami
et
al
also
suggest
inhibit
reduc
cardiovascular
risk
allcaus
mortal
diabet
patient
contrast
recent
metaanalysi
trial
particip
report
inhibitor
differ
allcaus
mortal
cv
mortal
acut
coronari
syndrom
stroke
compar
placebo
furthermor
inhibitor
show
statist
signific
increas
heart
failur
outcom
rr
ci
associ
inhibit
increas
risk
heart
failur
also
support
anoth
metaanalysi
monami
importantli
result
two
larg
scale
clinic
trial
complet
recent
also
support
cardioprotect
effect
inhibit
human
examin
studi
diabet
patient
recent
day
myocardi
infarct
unstabl
angina
requir
hospit
random
treatment
alogliptin
placebo
patient
follow
median
period
month
although
safeti
trial
design
answer
question
efficaci
alogliptin
treatment
improv
combin
outcom
primari
endpoint
includ
death
cardiovascular
caus
nonfat
myocardi
infarct
nonfat
stroke
trend
toward
reduct
cardiovascular
death
albeit
nonstatist
signific
total
subject
one
follow
cardiovascular
risk
histori
mi
atherosclerosi
hypertens
smoke
dyslipidemia
recruit
savortimi
evalu
effect
saxagliptin
cardiovascular
outcom
patient
random
saxagliptin
placebo
group
addit
antidiabet
agent
prescrib
throughout
studi
median
followup
time
year
maximum
year
consist
result
examin
improv
cardiovascular
outcom
observ
saxagliptin
treatment
group
compar
placebotr
patient
noteworthi
hospit
rate
heart
failur
higher
saxagliptintr
subject
versu
hazard
ratio
ci
differ
multipl
safeti
endpoint
pancreat
cancer
hypoglycemia
observ
across
group
savortimi
examin
trial
trial
suggest
catalyt
inhibit
basic
safe
cardiovascular
standpoint
also
improv
cardiovascular
endpoint
least
short
term
must
note
median
followup
period
examin
savortimi
year
year
respect
longer
followup
period
may
necessari
confirm
result
least
result
current
larg
scale
trial
suggest
catalyt
inhibit
alon
insuffici
improv
cardiovascular
outcom
ongo
trial
assess
cardiovascular
safeti
may
provid
insight
cardiovascular
effect
failur
anim
studi
suggest
inhibit
improv
cardiac
function
surviv
rate
heart
failur
gomez
et
al
report
activ
posit
associ
bodi
weight
adult
dog
significantli
higher
heart
failur
class
compar
healthi
heart
heart
failur
class
demonstr
might
involv
earli
stage
heart
failur
pressureoverloadinduc
heart
failur
anim
model
transvers
aortic
constrict
tac
takahashi
report
vildagliptin
amelior
tacinduc
left
ventricular
enlarg
dysfunct
improv
surviv
rate
day
tac
vildagliptin
tac
without
vildagliptin
accord
shigeta
et
al
demonstr
pharmacolog
genet
inhibit
revers
diabet
diastol
left
ventricular
dysfunct
pressureoverloadinduc
left
ventricular
dysfunct
improv
left
ventricular
function
assess
eject
fraction
mitral
annular
systol
veloc
peak
systol
veloc
also
observ
human
inhibit
sitagliptin
singl
dose
week
treatment
agonist
also
shown
increas
left
ventricular
eject
fraction
short
term
although
inconsist
despit
potenti
benefit
improv
cardiac
function
shortterm
use
analog
report
longterm
cardiovascular
effect
analog
limit
surprisingli
scirica
et
al
report
increas
hospit
admiss
rate
heart
failur
saxagliptintr
patient
compar
placebo
versu
hazard
ratio
ci
savortimi
trial
rais
question
whether
increas
risk
heart
failur
subsequ
metaanalysi
includ
trial
patient
monami
et
al
report
includ
vildagliptin
sitagliptin
saxagliptin
alogliptin
linagliptin
dutogliptin
increas
overal
risk
heart
failur
ci
although
result
heavili
influenc
savortimi
result
interestingli
anoth
metaanalysi
pool
random
control
studi
patient
assess
cardiovascular
safeti
saxagliptin
report
saxagliptin
increas
incid
rate
cardiovascular
event
includ
heart
failur
incid
rate
ratio
ci
heart
failur
studi
publish
juli
weir
et
al
evalu
effect
sitagliptin
januvia
cardiovascular
endpoint
allcaus
hospit
admissiondeath
well
heartfailurespecif
hospitalizationdeath
diabet
patient
recent
diagnos
heart
failur
although
sitagliptin
treatment
increas
risk
primari
endpoint
compon
hospit
admiss
death
note
associ
increas
risk
heart
failur
hospit
versu
ci
absolut
risk
associ
heart
failur
small
one
limit
metaanalysi
overlook
princip
critic
includ
studi
never
design
cardiovascular
signal
risk
factor
may
identifi
patient
risk
small
risk
seen
saxagliptin
savortimi
trial
scirica
et
al
report
patient
increas
risk
hospit
heart
failur
either
prior
heart
failur
elev
level
natriuret
peptid
chronic
kidney
diseas
howev
risk
primari
secondari
endpoint
similar
treatment
group
even
patient
high
risk
hospit
heart
failur
suggest
inhibit
saxagliptin
increas
death
myocardi
infarct
stroke
even
increas
risk
heart
failur
therefor
recent
find
may
limit
use
patient
cardiovascular
diseas
howev
use
caution
patient
increas
vulner
inhibitionassoci
heart
failur
especi
saxagliptin
histori
heart
failur
chronic
kidney
diseas
ongo
studi
teco
carmelina
carolina
inform
addit
risk
pose
agent
class
earli
studi
safeti
suggest
well
toler
minor
side
effect
gastrointestin
reaction
nausea
vomit
diarrhea
etc
flulik
symptom
skin
reaction
importantli
show
weight
gain
hypoglycem
risk
compar
oral
antidiabet
medic
consid
divers
function
safeti
longterm
usag
immun
function
antitumor
antiinfect
question
alter
express
level
report
mani
type
cancer
increas
pancreat
cancer
note
patient
take
sitagliptin
exenatid
compar
therapi
evidenc
evalu
us
fda
advers
event
databas
incid
cancer
similar
sitagliptin
group
control
drug
anoth
evalu
german
advers
event
databas
contrast
show
signific
associ
pancreat
cancer
sever
metaanalysi
report
indic
increas
risk
infect
nasopharyng
urinari
tract
infect
patient
howev
also
contradictori
report
infect
monami
et
al
report
metaanalysi
signific
increas
risk
nasopharyng
sitagliptin
mantelhaenszel
odd
ratio
mhor
ci
vildagliptin
signific
associ
upper
respiratori
tract
infect
urinari
tract
infect
observ
actual
incid
infect
lower
compar
group
also
studi
rais
concern
incretinbas
therapi
may
potenti
contribut
pancreat
howev
limit
clinic
data
examin
risk
pancreat
conclus
remain
uncertain
metaanalysi
includ
trial
pancreat
risk
show
signific
increas
pancreat
mhor
ci
noteworthi
number
observ
case
small
investig
need
confirm
result
elashoff
et
al
report
increas
pancreat
patient
treat
sitagliptin
compar
patient
treat
control
antidiabet
drug
contrast
recent
casecontrol
studi
includ
patient
firsttim
hospit
acut
pancreat
also
reveal
associ
acut
pancreat
develop
applic
specif
clinic
reemphas
import
physiolog
patholog
process
recent
studi
suggest
safe
cardiovascular
perspect
although
signific
improv
observ
cardiovascular
endpoint
patient
antidiabet
medic
howev
must
acknowledg
durat
two
trial
less
year
subject
medic
statin
may
interfer
cardiovascular
effect
notabl
least
one
trial
show
increas
heart
failur
hospit
patient
prior
heart
failur
chronic
kidney
diseas
suggest
use
caution
patient
absolut
risk
heart
failur
agent
small
agent
must
acknowledg
diabet
therapi
use
glycemia
control
sulfonylurea
thiazolidinedion
also
increas
risk
heart
failur
studi
requir
investig
exact
role
particularli
catalyt
independ
activ
cardiovascular
diseas
dr
jixin
zhong
quan
gong
aditya
goud
srividya
srinivasamaharaj
declar
conflict
interest
dr
sanjay
rajagopalan
receiv
fund
takeda
pharmaceut
